Abstract Title:

(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.

Abstract Source:

Exp Cell Res. 2015 May 15 ;334(1):136-45. Epub 2015 Apr 14. PMID: 25882496

Abstract Author(s):

Xiang Chang, Cuiping Rong, Yunbo Chen, Cong Yang, Qian Hu, Yousheng Mo, Chunxia Zhang, Xiaoqiong Gu, Lei Zhang, Wenqing He, Shuyi Cheng, Xueqin Hou, Ruyu Su, Sijun Liu, Wenjun Dun, Qi Wang, Shuhuan Fang

Article Affiliation:

Xiang Chang

Abstract:

Epigenetic changes are involved in learning and memory, and histone deacetylase (HDAC) inhibitors are considered potential therapeutic agents for Alzheimer's disease (AD). We previously reported that (-)-epigallocatechin-3-gallate (EGCG) acts as an HDAC inhibitor. Here, we demonstrate that EGCG reducedβ-amyloid (Aβ) accumulation in vitro and rescued cognitive deterioration in senescence-accelerated mice P8 (SAMP8) via intragastric administration of low- and high-dose EGCG (5 and 15 mg/kg, respectively) for 60 days. The AD brain has decreased levels of the rate-limiting degradation enzyme of Aβ, neprilysin (NEP). We found an association between EGCG-induced reduction in Aβ accumulation and elevated NEP expression. Further, NEP silencing prevented the EGCG-induced Aβ downregulation. Our findings suggest that EGCG might be effective for treating AD.

Study Type : Animal Study, In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.